Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 13/20 | 0.78 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.61 |
| ▸ | MAOA | P21397 | 7/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29369517 | 1.00 | MAOB (0.78) | MAOBMAPTCYP2C9CYP2C19SMN1; SMN2 | |
| SCHEMBL29466867 | 0.93 | MAOB (0.68) | MAOBMAPTCYP2C9CYP2C19SMN1; SMN2 | |
| SCHEMBL10797158 | 0.93 | MAOB (0.72) | MAOBMAPTCYP2C9CYP2C19SMN1; SMN2 | |
| SCHEMBL29184830 | 0.91 | MAOB (0.70) | MAOBMAPTCYP2C9CYP2C19SMN1; SMN2 | |
| SCHEMBL6450099 | 0.91 | MAOB (0.65) | MAOBMAPTCYP2C9CYP2C19SMN1; SMN2 | |
| SCHEMBL6035440 | 0.90 | MAOB (0.68) | MAOBMAPTCYP2C9CYP2C19SMN1; SMN2 | |
| SCHEMBL26455225 | 0.90 | MAOB (0.64) | MAOBMAPTCYP2C9CYP2C19SMN1; SMN2 | |
| SCHEMBL1962771 | 0.90 | MAOB (0.64) | MAOBMAPTCYP2C9CYP2C19SMN1; SMN2 | |
| SCHEMBL7726185 | 0.90 | MAOB (0.68) | MAOBMAPTCYP2C9CYP2C19SMN1; SMN2 | |
| SCHEMBL2785214 | 0.89 | MAOB (0.71) | MAOBMAPTCYP2C9CYP2C19SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 176 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109020883-B | 3-cyano-2-aminopyridine derivative and preparation method and application thereof | 广西民族大学 | 2022-02-08 | — | — | CN | claimed |
| EP-0728128-B1 | SUBSTITUTED PHENYL COMPOUNDS | RHONE POULENC RORER LTD (GB) | 1998-09-16 | — | — | EP | claimed |
| EP-0728128-A1 | SUBSTITUTED PHENYL COMPOUNDS | RHONE-POULENC RORER LIMITED (GB) | 1996-08-28 | — | — | EP | claimed |
| WO-1995013262-A1 | SUBSTITUTED PHENYL COMPOUNDS | RHONE-POULENC RORER LIMITED (GB) | 1995-05-18 | — | — | WO | claimed |
| US-12227472-B2 | Series of skin-whitening (lightening) compounds | UNIGEN, INC. (US) | 2025-02-18 | — | — | US | disclosed |
| US-20230399282-A1 | Series of Skin-Whitening (Lightening) Compounds | UNIGEN, INC. (US) | 2023-12-14 | — | — | US | disclosed |
| US-11739040-B2 | Series of skin-whitening (lightening) compounds | UNIGEN, INC. (US) | 2023-08-29 | — | — | US | disclosed |
| US-20230139366-A1 | BRARTEMICIN ANALOGUES | VICTORIA LINK LIMITED (NZ) | 2023-05-04 | — | — | US | disclosed |
| US-11479528-B2 | Heat shock protein 90 inhibitors | TAIPEI MEDICAL UNIVERSITY (TW) | 2022-10-25 | — | — | US | disclosed |
| EP-4046619-A1 | SERIES OF SKIN-WHITENING (LIGHTENING) COMPOUNDS | Unigen, Inc. (US) | 2022-08-24 | — | — | EP | disclosed |
| CN-109020883-B | 3-cyano-2-aminopyridine derivative and preparation method and application thereof | 广西民族大学 | 2022-02-08 | — | — | CN | disclosed |
| US-11234987-B2 | Isoxazole compounds as inhibitors of heat shock proteins | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2022-02-01 | — | — | US | disclosed |
| EP-0728128-A1 | SUBSTITUTED PHENYL COMPOUNDS | RHONE-POULENC RORER LIMITED (GB) | 1996-08-28 | — | — | EP | disclosed |
| US-5428059-A | Benzopyran derivatives and an anti-allergic agent possessing the same as the active ingredient | DAINIPPON INK & CHEMICALS, INC. (JP) | 1995-06-27 | — | — | US | disclosed |
| WO-1995013262-A1 | SUBSTITUTED PHENYL COMPOUNDS | RHONE-POULENC RORER LIMITED (GB) | 1995-05-18 | — | — | WO | disclosed |
| EP-0598117-A1 | BENZOPYRAN DERIVATIVE AND ANTIALLERGIC AGENT CONTAINING THE SAME AS ACTIVE INGREDIENT | DAINIPPON INK AND CHEMICALS, INC. (JP) | 1994-05-25 | — | — | EP | disclosed |
| WO-1992012981-A1 | SUBSTITUTED PHENYL-1,3 DIOXOLOQUINOLINE DERIVATIVES AND THEIR USE AS ANTITUMOR AGENTS | GLAXO INC. (US) | 1992-08-06 | — | — | WO | disclosed |
| EP-0496634-A1 | Substituted phenyl-1,3-dioxoloquinoline derivatives and their use as antitumor agents | GLAXO INC. (US) | 1992-07-29 | — | — | EP | disclosed |
| US-5126351-A | Inhibitors of topoisomerase | GLAXO INC. (US) | 1992-06-30 | — | — | US | disclosed |
| US-3952021-A | α-(3,4-Dimethoxyphenethylaminomethyl)-3,4 or 3,5-dihydroxybenzylalcohols and salts thereof | TANABE SEIYAKU CO., LTD. (JA) | 1976-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230139366-A1 | BRARTEMICIN ANALOGUES | RXFP1, RXFP2, RXFP4 | MAOB 4572/4885MAPT 4232/4885CYP2C9 4791/4885 |
| US-11739040-B2 | Series of skin-whitening (lightening) compounds | TYR, TH, MAOB | MAOB 3/4885MAPT 372/4885CYP2C9 129/4885 |
| US-20230399282-A1 | Series of Skin-Whitening (Lightening) Compounds | TYR, TH, MAOB | MAOB 3/4885MAPT 372/4885CYP2C9 129/4885 |
| US-11234987-B2 | Isoxazole compounds as inhibitors of heat shock proteins | HSP90AB1, HSP90AA1, HSP90AB2P | MAOB 3440/4885MAPT 4418/4885CYP2C9 1533/4885 |
| US-11479528-B2 | Heat shock protein 90 inhibitors | HSP90AB1, HSP90AB2P, HSP90AA1 | MAOB 3544/4885MAPT 1750/4885CYP2C9 4003/4885 |
| US-12227472-B2 | Series of skin-whitening (lightening) compounds | TYR, TH, MAOB | MAOB 3/4885MAPT 372/4885CYP2C9 129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.